Immunic (IMUX) Insider Joerg Neermann Buys 25,370 Shares
Joerg Neermann acquired 25,370 shares of IMUX on June 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Joerg Neermann bought 25,370 shares of Immunic, Inc. ($IMUX) on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IMUX is down 3.6% after 1 week, down 15.3% after 1 month and down 54.8% to date (from the $15.41 close on Jun 29, 2026).
IMUX
Immunic, Inc.
Key Points
- Joerg Neermann purchased 25,370 shares of IMUX on June 29, 2026.
- IMUX shares traded near $15.30 on Tuesday, with various insiders also buying.
- Analysts maintained a 'buy' rating, with price targets up to $27.
Get $IMUX trade alerts by text
We text you when insiders, Congress or big funds trade $IMUX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immunic, Inc. alert may contain errors. Disclosures
Joerg Neermann recently purchased 25,370 shares of IMUX on June 29, 2026. This insider buying activity occurred as shares of IMUX traded near $15.30 on Tuesday. The transaction wasn't planned under a Rule 10b5-1 plan, indicating a direct acquisition.
Insider Buying and Selling at Immunic, Inc.
Several insiders at IMUX made notable purchases on June 29, 2026. Jon Congleton bought 50,740 shares, while Jason Tardio, the President and COO, acquired 253,000 shares. The Chief Financial Officer, Glenn Whaley, also purchased 120,000 shares. Daniel Vitt and Tamar Howson each bought 445,000 and 25,370 shares, respectively.
Other Institutional Activity in IMUX
Among institutional investors, Aberdeen Group PLC and BVF Inc/IL significantly reduced their holdings, each cutting their stakes by 90%. Aberdeen Group PLC now holds 824,394 shares valued at about $9.15 million, while BVF Inc/IL has 765,297 shares worth approximately $8.49 million. Avidity Partners Management LP also trimmed its position by 85.7%, leaving it with 669,941 shares valued at $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. opened new positions with 513,832 and 450,000 shares, respectively.
Analysts Set New Price Targets
On May 22, 2026, B. Riley Securities maintained a 'buy' rating on IMUX, setting a price target of $27. HC Wainwright & Co. also reiterated its 'buy' rating with a $22 target on April 30. Earlier, Stifel initiated coverage with a 'buy' rating and a $2.5 target on April 17. Overall, the consensus remains positive, with multiple firms maintaining 'buy' ratings.
Bottom Line
Joerg Neermann's purchase of IMUX shares highlights ongoing interest from insiders at the company. With shares trading near $15.30, this buying activity suggests confidence in IMUX's prospects. Institutional movements show both reductions and new positions, reflecting varied strategies among investors. Analyst ratings remain supportive, with targets reaching up to $27, indicating optimism about the company's future performance.
Related Filing Alerts
Source: Joerg Neermann's Form 4 filing on $IMUX (Jun 29, 2026). Find the original filing: IMUX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts